Supernus director granted RSUs and stock options

Sensenig Bethany reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Sensenig Bethany reported acquisition or exercise transactions in this Form 4 filing.

SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig received new equity awards in the form of restricted stock units and stock options. She was granted 2,989 restricted stock units, each representing one share of Supernus common stock, and 4,977 director stock options.

The restricted stock units will be settled in common stock when they vest on February 18, 2027. The director stock options also vest on February 18, 2027. These awards increase Sensenig’s equity-based stake in the company but do not involve any open‑market share purchases or sales.

Insider Trade Summary

Grant/Award: 7,966 shares

Grant/Award 2 txns

Insider Sensenig Bethany

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	2,989	$0.00	$0.00
Grant/Award	Director Stock Option (Right to Buy)	4,977	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 2,989 contracts (Direct); Director Stock Option (Right to Buy) — 4,977 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
2. F2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
3. F3. Each option vests on February 18, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SUPN director Bethany Sensenig report?

Bethany Sensenig reported receiving equity awards, not open-market trades. She was granted 2,989 restricted stock units and 4,977 director stock options, both classified as acquisitions under a grant or award, increasing her potential future ownership in Supernus common stock when they vest.

How many restricted stock units did Bethany Sensenig receive from SUPN?

She received 2,989 restricted stock units. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting, giving her a potential claim on 2,989 shares once the vesting conditions are satisfied on the specified vesting date.

When do Bethany Sensenig’s SUPN restricted stock units vest?

Her restricted stock units vest on February 18, 2027. At that time, the units will be settled in shares of Supernus common stock, converting the award into actual share ownership, assuming she continues to meet any applicable service or eligibility requirements until vesting.

What stock option grant did Bethany Sensenig receive from SUPN?

She received 4,977 director stock options described as a right to buy Supernus common stock. These options were granted as an acquisition award and increase her potential ability to purchase shares once the options vest and become exercisable under their terms.

When do Bethany Sensenig’s SUPN director stock options vest?

Each of her director stock options vests on February 18, 2027. After vesting, the options provide the right to buy shares of Supernus common stock, subject to the option terms, giving her additional potential equity exposure to the company’s future performance.

Were Bethany Sensenig’s SUPN transactions open-market buys or sales?

No, the transactions were not open-market buys or sales. They are coded as acquisitions from grants or awards, involving restricted stock units and director stock options, reflecting compensation-related equity grants rather than discretionary trading in Supernus common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sensenig Bethany

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/18/2026		A		2,989		(2)	(2)	Common Stock	2,989	$0	2,989	D
Director Stock Option (Right to Buy)	$50.2	02/18/2026		A		4,977		(3)	02/18/2036	Common Stock	4,977	$0	4,977	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.

3. Each option vests on February 18, 2027.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.